Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
- Julio Rosenstock,
- Ronnie Aronson,
- George Grunberger,
- Markolf Hanefeld,
- PierMarco Piatti,
- Pierre Serusclat,
- Xi Cheng,
- Tianyue Zhou,
- Elisabeth Niemoeller,
- Elisabeth Souhami,
- Melanie Davies and
- , on behalf of the LixiLan-O Trial Investigators
In the Research Design and Methods section of the abstract of the above-mentioned article, the value of “<5.6 mmol/mol” should read “<5.6 mmol/L.”
The online issue has been corrected to reflect this change.
- © 2017 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
In this Issue
June 2017, 40(6)
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
